nmo spectrum disorders: closer to a rational pharmacotherapy? report from ectrims
Published 7 years ago • 319 plays • Length 14:57Download video MP4
Download video MP3
Similar videos
-
42:27
review of neuromyelitis optica
-
15:53
multiple sclerosis: advances in management- report from ectrims
-
6:43
sean pittock, ectrims 2022: phase 3 champion-nmosd trial results – ravulizumab for aqp4-igg nmosd
-
4:56
eculizumab: a review in neuromyelitis optica spectrum disorder
-
4:09
neuromyelitis optica spectrum disorder, causes, signs and symptoms, diagnosis and treatment.
-
5:49
new method for nmo testing at mayo clinic
-
48:53
latest developments in neuromyelitis optica spectrum disorder
-
20:19
nmosd multidisciplinary approach webinar, 25 june 2021 - dr. suzan ibrahim noori
-
21:23
2022 pre-rnds | neuromyelitis optica spectrum disorder (nmosd)
-
3:18
identifying risk factors for aqp4 nmosd
-
10:40
nmo: a spectrum?
-
6:10
new treatments for neuromyelitis optica in the pipeline
-
1:11
ectrims 2018 - predictive factors in nmosd
-
1:49
satralizumab in patients with nmosd and concomitant autoimmune diseases
-
1:51
selecting treatment options for nmosd
-
0:43
avery's nmosd story
-
1:39
recent progress and future needs in nmosd treatment
-
16:35
: ms treatment the oral agent era: how are things stacking up? report from ectrims
-
5:12
efficacy of inebilizumab in patients with nmosd with fc receptor iii-a polymorphisms